TW201542242A - Ophthalmic composition for negative ion soft contact lenses - Google Patents

Abstract

In an ophthalmic composition for negative ion SCLs which contains pranoprofen and/or a salt thereof, the present invention purports to provide a technique for suppressing adsorption of the pranoprofen and/or salt thereof to the negative ion SCLs. By causing this negative ion SCL ophthalmic composition containing pranoprofen and/or a salt thereof to contain taurine and/or a salt thereof and setting the pH to 7.7 or less, adsorption of the pranoprofen and/or salt thereof to negative ion SCLs can be effectively suppressed.

Description

Ophthalmic composition for anionic soft contact lenses Field of invention

The present invention relates to an ophthalmic composition for anionic soft contact lenses which can inhibit the adsorption of pranoprofen and/or a salt thereof to an anionic soft contact lens. Further, the present invention relates to a method for inhibiting adsorption of pranoprofen and/or a salt thereof to an anionic soft contact lens.

Background of the invention

In recent years, disposable contact lenses that can be worn continuously for a long time (hereinafter also referred to as SCL) have been developed, and SCL wearers continue to increase. As SCL, various surface characteristics such as anionic, zwitterionic, and nonionic have been developed, and anionic SCL has an excellent oxygen permeability and a small corneal burden, and has been widely used in recent years. Therefore, in order to improve the convenience of an anionic SCL wearer, an eye drop (anionic SCL eyedrop) which can be used in the state of wearing an anionic SCL is required.

Regarding the eye drops for SCL, the formulation must be designed to exert the desired effect, and it does not adversely affect SCL. In particular, if the drug in the eye drop agent for SCL is adsorbed on SCL, the lens may be deformed, the feeling of use may be lowered, and the like, and the desired pharmacological effect may not be obtained for the eye mucosa. Therefore, in the formulation design of the eye drops for SCL, it has become a particularly important issue to inhibit drug adsorption on SCL. Moreover, the adsorption characteristics of the drug vary depending on the surface characteristics of the SCL, so the formulation of the eye drop agent for SCL must be designed to correspond to the material of the SCL to be applied.

On the other hand, pranoprofen and/or its salt has a function of inhibiting the biosynthesis of prostaglandins which cause inflammation or pain. In the field of ophthalmology, the symptoms such as congestion or itching of the eyes are alleviated, and orbital inflammation, conjunctivitis, It is widely used for the purpose of prevention or treatment of scleritis, postoperative inflammation, anterior uveitis, and the like including upper scleritis. Several formulation techniques for eye drops for SCL containing pranoprofen and/or a salt thereof have also been proposed. For example, Patent Document 1 discloses an ophthalmic composition for a nonionic polyoxygen hydrogel contact lens containing vitamin A and taurine, which inhibits lipid adsorption in a nonionic polyoxygen hydrogel contact lens. surface. However, Patent Document 1 does not disclose that pranoprofen is adsorbed to SCL, and there is no disclosure of a technique applicable to anionic SCL.

Further, in the past, there have been studies on a formulation technique for inhibiting drug adsorption to SCL. For example, Patent Document 2 discloses that a basic drug selected from (A) an amine having a 2-stage amine group and/or a 3-stage amine group and a salt thereof, and (B) containing an amino acid and A composition for a soft contact lens having a salt, an acid mucopolysaccharide and a salt thereof, and a cyclodextrin selected from one or more substances and having a pH of 3.5 to 4.8, which inhibits adsorption of an alkaline drug to SCL. However, Patent Document 2 does not discuss any inhibition of the adsorption of pranoprofen on anionic SCL, and since the pH has to be set to 3.5 to 4.8, there is a problem in terms of formulation design restrictions.

Advanced technical literature Patent literature

Patent Document 1: Japanese Patent Laid-Open No. 2011-111425

Patent Document 2: International Publication No. 2007/77783

Summary of invention

In the past, pranoprofen and/or its salt have been noted, but its adsorption characteristics for anionic SCL have not been discussed at all. Under the circumstances, the inventors have confirmed that the adsorptivity of pranoprofen and/or its salt is higher than that of the nonionic SCL compared with the nonionic SCL (see Test Example 1 described later). Therefore, in order to practically use an ophthalmic composition containing an anionic SCL containing pranoprofen and/or a salt thereof, it is urgent to establish that pranoprofen and/or a salt thereof can be inhibited from being adsorbed to an anionic SCL.

Here, the present invention is directed to an ophthalmic composition for anionic SCL containing pranoprofen and/or a salt thereof, and to provide a technique for inhibiting adsorption of pranoprofen and/or a salt thereof to an anionic SCL.

In order to solve the above problems, the present inventors have found that an ophthalmic composition for anionic SCL containing pranoprofen and/or a salt thereof contains taurine and/or a salt thereof, and By setting the pH to 7.7 or less, it is possible to effectively suppress the adsorption of pranoprofen and/or its salt to the anionic SCL. Further, it has been found that a clear appearance property can be achieved by setting the pH of the anionic SCL ophthalmic composition to 5.5 or more. this invention Based on this insight, and completed by repeated discussions.

That is, the present invention provides the invention of the following disclosed aspects.

Item 1. An ophthalmic composition for an anionic soft contact lens, comprising pranoprofen and/or a pharmaceutically acceptable salt thereof, and taurine and/or a pharmaceutically acceptable salt thereof, and having a pH of Below 7.7.

Item 2. The ophthalmic composition for an anionic soft contact lens according to Item 1, which has a pH of from 5.5 to 7.7.

The ophthalmic composition for anionic soft contact lenses according to Item 1 or 2, which contains 0.01 to 3 w/v% of taurine and/or a pharmaceutically acceptable salt thereof.

The ophthalmic composition for an anionic soft contact lens according to any one of items 1 to 3, which contains 0.001 to 0.5 w/v% of pranoprofen and/or a pharmaceutically acceptable salt thereof.

The ophthalmic composition for an anionic soft contact lens according to any one of items 1 to 4, which is an eye drop for an anionic soft contact lens.

Item 6. A method for inhibiting adsorption of pranoprofen and/or a pharmaceutically acceptable salt thereof to an anionic soft contact lens, characterized by an anionic soft type containing pranoprofen and/or a pharmaceutically acceptable salt thereof To the ophthalmic composition for contact lenses, taurine and/or a pharmaceutically acceptable salt thereof is added, and the pH is adjusted to 7.7 or less.

Item 7. Use of a liquid preparation for producing an ophthalmic composition for an anionic soft contact lens, the liquid preparation containing pranoprofen and/or a pharmaceutically acceptable salt thereof, and taurine and/or its pharmacy The salt is allowed to have a pH of 7.7 or less.

According to the ophthalmic composition for anionic SCL of the present invention, Since inhibition of pranoprofen and/or its salt is adsorbed to anionic SCL, it does not adversely affect anionic SCL, and can effectively exert the pharmacological effect of pranoprofen and/or its salt. Moreover, the ophthalmic composition for anionic SCL of the present invention, wherein taurine and/or a salt thereof not only exerts an action of inhibiting adsorption of pranoprofen and/or a salt thereof to an anionic SCL, but also promotes metabolism of the eye. The effect is synergistic with the efficacy of pranoprofen and/or its salt, and it can also achieve excellent prevention of eye diseases and recovery.

Further, in the ophthalmic composition for anionic SCL of the present invention, by setting the pH to 5.5 or more, it is possible to suppress white turbidity caused by pranoprofen and/or a salt thereof, and to provide a clear appearance property. An ophthalmic composition for anionic SCL. In the present specification, the term "clear" means that the turbidity caused by pranoprofen and/or its salt is not caused, and it is not limited to colorless and clear, and includes colored and clear colors which are colored according to other components. concept.

Form for implementing the invention

1. Anionic SCL ophthalmic composition

The ophthalmic composition for anionic SCL of the present invention is characterized by containing pranoprofen and/or a pharmaceutically acceptable salt thereof, and taurine and/or a pharmaceutically acceptable salt thereof, and having a pH of 7.7 or less. Hereinafter, the ophthalmic composition for anionic SCL of the present invention will be described in detail. In addition, in the present specification, the "ophthalmic composition for anionic SCL" refers to the field of ophthalmology and is used in the field of ophthalmology. A composition used in the form of contact with an anionic SCL. Further, in the present specification, the concentration unit "w/v%" of each component means the mass-to-capacity percentage, which is synonymous with g/100 mL.

The ophthalmic composition for anionic SCL of the present invention contains pranoprofen and/or a salt thereof. Praprofene, also known as α-methyl-5H-[1]benzopyrano[2,3-b]pyridine-7-acetic acid, is a well-known compound known to have an anti-inflammatory effect in the ophthalmology field.

The salt of pranoprofen is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include metal salts such as sodium salts, potassium salts, calcium salts, magnesium salts, and aluminum salts; and triethylamine salts and An organic base salt such as an ethylamine salt, a wortrine salt or a piperazine salt. These salts of pranoprofen may be used alone or in combination of two or more.

In the ophthalmic composition for anionic SCL of the present invention, one of pranoprofen and a salt thereof may be used alone or in combination of two or more. Among pranoprofen and its salts, pranoprofen is preferred.

In the ophthalmic composition for anionic SCL of the present invention, the concentration of pranoprofen and/or a salt thereof can be appropriately set depending on the use of the ophthalmic composition for anionic SCL, and the like, for example, 0.001~ 0.5 w/v%, preferably 0.01 to 0.2 w/v%, more preferably 0.01 to 0.1 w/v%.

The ophthalmic composition for anionic SCL of the present invention further contains taurine and/or a salt thereof. In the ophthalmic composition for anionic SCL of the present invention, pranoprofen and/or a salt thereof is allowed to coexist with taurine and/or a salt thereof to inhibit adsorption of pranoprofen and/or a salt thereof to an anionic property. SCL has become feasible.

Taurine is also known as amino ethanesulfonic acid and its chemical name is 2-amino B. Sulfonic acid. In the field of ophthalmology, it is also a known compound which is used for the purpose of promoting eye metabolism and the like.

The salt of taurine is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include an alkali metal salt such as a sodium salt or a potassium salt. These salts of taurine may be used alone or in combination of two or more.

The ophthalmic composition for anionic SCL of the present invention may be used alone or in combination of two or more kinds of taurine or a salt thereof. Among the taurine and its salts, taurine is preferred.

In the ophthalmic composition for anionic SCL of the present invention, the concentration of taurine and/or a salt thereof is, for example, 0.01 to 3 w/v%. In particular, from the viewpoint of more effectively inhibiting adsorption of pranoprofen and/or a salt thereof to anionic SCL, the concentration of taurine and/or a salt thereof is 0.1 to 3 w/v%. Good is 0.1~1w/v%.

The pH of the ophthalmic composition for anionic SCL of the present invention is set to 7.7 or less. The ophthalmic composition for anionic SCL of the present invention inhibits pranoprofen by allowing the pranoprofen and/or its salt to coexist with taurine and/or a salt thereof, and setting it to such a pH range And / or its salt becomes feasible by adsorption to anionic SCL.

Further, as shown in the test example described later, it was confirmed that the composition containing pranoprofen and/or its salt was white turbid due to pranoprofen and/or its salt when the pH was 4.5 or less. Setting the pH to 5.5 or more gives a clear appearance property. In view of the above, the pH of the ophthalmic composition for anionic SCL of the present invention is more effective in suppressing adsorption of pranoprofen and/or its salt to anionic SCL and having a clear appearance property. From the point of view, it is preferably 5.5 to 7.7, and preferably 6.5 to 7.7, more preferably 6.5 to 7.4, and most preferably 6.5 to 7.0.

When the pH of the ophthalmic composition for anionic SCL of the present invention is to be adjusted to the above range, a pH adjuster or a buffer which is generally used in an ophthalmic composition may be used. Examples of the pH adjuster include a base such as sodium hydroxide or potassium hydroxide; and an acid such as acetic acid, citric acid, hydrochloric acid, phosphoric acid or tartaric acid. These pH adjusters may be used alone or in combination of two or more. Further, examples of the buffering agent include a phosphate buffer, a boric acid buffer, a citrate buffer, a tartaric acid buffer, an acetate buffer, an amino acid, and a tris. These buffers may be used alone or in combination of two or more.

In addition to the above-mentioned components, the ophthalmic composition for anionic SCL of the present invention may contain a pharmacological component other than pranoprofen and/or a salt thereof as needed. Examples of the pharmacological component include dipotassium glycyrrhizinate, allantoin, □-amine hexanoic acid, bromfenac, ketorolac tromethamine, nepafenac, berberine chloride, and sulfate sulphate. Anti-inflammatory agents such as alkali, sodium sulfonate, zinc sulfate, zinc lactate, lysozyme hydrochloride; antihistamines such as chlorpheniramine maleate and diphenhydramine hydrochloride; sodium cromolyn and fumarate Anti-allergic agents such as fen, azastat, amlexanox, pyrazostat potassium, tranilast, and ibudilast; norfloxacin, ofloxacin, lomefloxacin, levofloxacin, See antibacterial agents such as gentamicin, gatifloxacin; ascorbic acid, flavin adenine dinucleotide sodium, cyanocobalamin, pyridoxine hydrochloride, tocopherol acetate, retinol acetate, retinyl palmitate Esters such as esters, panthenol, calcium pantothenate, and sodium pantothenate; amino acids such as aspartame, sodium chondroitin sulfate, and methyl sulphate neostigmine Cholinesterase; vasoconstrictor such as nepyrimazine, tetrahydrozoline, adrenaline, ephedrine, phenylephrine, dl-methylephedrine; isotonic conjunctival epithelium of sodium gluconate Barrier therapeutic agent; sulfadiazine, sulfamethoxazole, sulfamethazine, sulfamethoxine, sulfamethoxazole, sulfamethoxazole, sulfonamide, sulfamethoxazole, sulfamethoxazole, sulfamethoxazole , phthalic acid such as phthalic acid sulfamethoxazole or amber sulfamethoxazole. The compounds exemplified herein may be in the form of a salt or may be in the form of other salts as long as they are pharmaceutically acceptable. These pharmacological components may be used alone or in combination of two or more.

The concentration of the pharmacological components can be appropriately set depending on the type of the pharmacological component or the use of the anionic SCL for the ophthalmic composition.

Further, in the ophthalmic composition for anionic SCL of the present invention, in addition to the above components, an isotonic agent, a dissolution aid, a thickener, a chelating agent, a cooling agent, a preservative, and a stabilizer may be contained as needed. Additives such as surfactants.

Examples of the isotonic agent include sugars such as sorbitol, glucose, and mannitol; polyvalent alcohols such as glycerin and propylene glycol; salts such as sodium chloride; and boric acid. The above-mentioned tonicity agents may be used singly or in combination of two or more.

Examples of the dissolution aid include nonionic surfactants such as sorbitan monopolyethylene, polyoxyethylene hardened castor oil, tyloxapol, and pluronic; polyvalent alcohols such as glycerin and polyethylene glycol; and the like. . These dissolution aids may be used alone or in combination of two or more.

Examples of the thickener include water-soluble polymers such as polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, carboxyvinyl polymer, trimec gum, sodium chondroitin sulfate, and sodium hyaluronate; hydroxypropylmethyl Cellulose such as cellulose, hydroxyethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, and the like. These thickeners may be used alone or in combination of two or more.

Examples of the chelating agent include edetate, citric acid or a salt thereof. These tongs may be used alone or in combination of two or more.

Examples of the cooling agent include 1-menthol, borneol, camphor, and eucalyptus oil. These cooling agents may be used alone or in combination of two or more.

Examples of the preservative include sorbic acid or a salt thereof, benzoic acid or a salt thereof, methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate, chlorobutanol, and lohexedine gluconate. Boric acid, dehydroacetic acid or its salt, benzalkonium chloride, benzethonium chloride, benzyl alcohol, zinc chloride, p-chloro-xylenol, chloromethylphenol, benzyl alcohol, beryl ammonium chloride, Sodium amalgamate, dibutylhydroxytoluene, and the like. These preservatives may be used alone or in combination of two or more.

Examples of the stabilizer include polyvinylpyrrolidone, sulfite, monoethanolamine, glycerin, propylene glycol, cyclodextrin, polydextrose, ascorbic acid, edetate, tocopherol, dibutylhydroxytoluene, and the like. These stabilizers may be used alone or in combination of two or more.

As the surfactant, tirofloxacin, polyoxyethylene hardened castor oil, polyoxyethylene polyoxypropylene block copolymer, polyoxyethylene sorbent Nonionic surfactants such as alcohol anhydride fatty acid esters and octyl phenols; amphoteric surfactants such as alkyldiamine ethylglycine and lauryl dimethylamine acetate; alkyl sulfates, N- An anionic surfactant such as a mercapto taurinate, a polyoxyethylene alkyl ether phosphate or a polyoxyethylene alkyl ether sulfate; a cationic surfactant such as an alkyl pyridinium salt or an alkylamine salt. These surfactants may be used alone or in combination of two or more.

The concentration of the additives can be appropriately set depending on the type of the additive or the use of the anionic SCL for the ophthalmic composition.

The preparation form of the ophthalmic composition for anionic SCL of the present invention may be a liquid preparation containing water as a base, and may be, for example, an aqueous solution or an emulsion, and examples thereof include an aqueous solution. Good.

The ophthalmic composition for anionic SCL of the present invention may be produced according to a known method according to the use thereof, and can be produced, for example, by the method described in the sixteenth revised Japanese Pharmacopoeia.

The ophthalmic composition for anionic SCL of the present invention can be used as an eye-dropping agent for anionic SCL or an eye-dropping agent for anionic SCL (anionic SCL eyedrop agent); an anionic SCL can also be used as an eye-washing agent for eye wash. (an anionic SCL eye wash); a contact liquid for an anionic SCL, a multifunctional solution for an anionic SCL, a cleaning solution for an anionic SCL, a contact lens maintenance solution for an anionic SCL, and the like. Among these, an eye drop for anionic SCL and an eye wash for anionic SCL are preferred, and an eye drop for anionic SCL is more preferred.

The anionic SCL to which the present invention is applied is an SCL containing a polymer containing an anionic group-containing monomer as a constituent material. As The anionic SCL may, for example, be a SCL having a polymer having an anionic group such as a carboxyl group, a sulfo group or a phosphoric acid group as a constituent material, and more specifically, it is etafilcon A and vifilcon A. ), SCU of materials such as Ocufilcon D and MethafilconA. The materials and manufacturing methods of anionic SCL are well known.

Further, the anionic SCL to which the present invention is applied may be either a high water content or a low water content, and may be exemplified by a group having a high water content, that is, a group classified by the US Food and Drug Administration (FDA). (Ionic monomer 1 mol% or more, water content 50% or more) is preferred.

2. Method for inhibiting adsorption of pranoprofen and/or its salt to anionic SCL (1)

Further, the present invention provides a method for inhibiting adsorption of pranoprofen and/or a salt thereof to an anionic SCL, which comprises an ophthalmic composition comprising an anionic SCL containing pranoprofen and/or a pharmaceutically acceptable salt thereof To the mixture, taurine and/or a pharmaceutically acceptable salt thereof is added, and the pH is adjusted to 7.7 or less. This inhibition adsorption method is advantageous for imparting an effect of inhibiting adsorption of pranoprofen and/or a salt thereof to an anionic SCL to an ophthalmic composition for anionic SCL.

In the method for inhibiting adsorption according to the present invention, the type and concentration of pranoprofen and/or a pharmaceutically acceptable salt thereof, the type and concentration of taurine and/or a pharmaceutically acceptable salt thereof, and anionicity The pH value of the ophthalmic composition for SCL, the type of the pharmacological component and the additive to be added to the anionic SCL ophthalmic composition, the formulation type and use of the anionic SCL ophthalmic composition, and the anionic SCL to be applied. The type and the like are as described in the column "1. Ophthalmic composition for anionic SCL". Loaded.

3. Method for inhibiting adsorption of pranoprofen and/or its salt to anionic SCL (2)

Further, the present invention provides a method for inhibiting adsorption of pranoprofen and/or a salt thereof to an anionic SCL, which comprises containing pranoprofen and/or a pharmaceutically acceptable salt thereof, taurine and/or a pharmaceutical thereof A step of contacting a liquid agent having a salt of 7.7 or less with an anionic SCL.

In the method for inhibiting adsorption according to the present invention, the type and concentration of pranoprofen and/or a pharmaceutically acceptable salt thereof, the type and concentration of taurine and/or a pharmaceutically acceptable salt thereof, and a liquid agent The pH value, the type of the pharmacological component and the additive to be added to the liquid preparation, the formulation type and use of the liquid preparation, and the type of the anionic SCL to be applied are as described above. 1. The ophthalmic composition for anionic SCL is as described above. It is recorded in the column. Further, in the method for inhibiting adsorption according to the present invention, the method of bringing the liquid agent into contact with the anionic SCL may be appropriately set depending on the use of the liquid agent. For example, when the liquid agent is an eye drop, the liquid agent may be spotted against the eye wearing an anionic SCL.

Example

The invention will be exemplified and described in detail below, but the invention is not limited by the examples.

Test example 1

The components shown in Table 1 were mixed in a usual manner to prepare a test solution. The appearance of each of the obtained test liquids was observed, and the turbidity (absorbance at 660 nm) was measured to evaluate the presence or absence of white turbidity.

Separately, 3 mL of each test solution was placed in a vial, and one SCL was immersed therein, and shaken at 25 ° C for 2 hours or more. Further, 3 mL of each test solution was placed in a vial and shaken at 25 ° C for 2 hours or more in a state where no SCL was immersed therein. After the shaking, the content of pranoprofen in each test solution was measured by liquid chromatography, and the amount of pranoprofen adsorbed on SCL was calculated according to the following formula. Further, it has been confirmed that when the SCL is immersed in the test liquid, the adsorption is achieved within 2 hours due to the adsorption of pranoprofen on the SCL, and the oscillation time is set to 2 hours or more on the SCL. The measured value of the amount of pranoprofen adsorbed does not have an effect.

[Number 1] The amount (μg) of pranoprofen adsorbed to one SCL = (CC-CT) × V

CC: Praprofene content (μg/mL) in test solution without SCL impregnation

CT: Praprofene content (μg/mL) in test solution with SCL impregnation

V: amount of test solution used in the test (mL)

Further, in the present experiment, the following two kinds of SCL were used, and the amount of adsorption of pranoprofen for each SCL was determined.

Lens 1: Group IV, sold under the name "1-day acuvue (registered trademark)" (manufactured by Johnson & Johnson Co., Ltd.), anionic, USAN name: etafilcon A

Lens 2: Polyoxygenated Hydrogel Contact Lens, Group I, sold under the name "AIR OPTIX 2-week (registered trademark)" (manufactured by CIBA Vision Co., Ltd.), USAN name: lotrafilcon B

The results obtained are shown in Table 1. From the results of Comparative Example 5, it was confirmed that the anionic SCL phase was invisible to the nonionic polyoxygen hydrogel. Mirror, pranoprofen has a large amount of adsorption. On the other hand, in the test liquid (Examples 1 to 3) containing pranoprofen and taurine and having a pH of 7.7 or less, the adsorption of pranoprofen on the anionic SCL was remarkably suppressed. On the other hand, in the test liquid containing pranoprofen and taurine at a pH of 8.0 or more (Comparative Examples 2 and 4), not only the pranoprofen adsorption was inhibited compared to the case where no taurine was contained. In the case of anionic SCL, it also contributes to the phenomenon. From the above results, it is clear that the adsorption of pranoprofen to anionic SCL can be suppressed by containing pranoprofen, taurine and/or a salt thereof and setting the pH to 7.7 or less. Further, all of the test liquids having a pH of 5.5 or more were not confirmed to be cloudy, and exhibited a clear appearance property.

In the table, the unit of the added amount of each added component is "w/v%". Further, n.m. indicates that it was not measured.

Test example 2

The components shown in Tables 2 and 3 were mixed in a usual manner to prepare a test solution. The appearance of each of the obtained test liquids was observed, and the turbidity (absorbance at 660 nm) was measured to evaluate the presence or absence of white turbidity. Further, the amount of pranoprofen adsorbed on the anionic SCL was measured in the same manner as in the above Test Example 1 for each of the obtained test solutions.

The results obtained are shown in Tables 2 and 3. From this result, it was confirmed that the adsorption of pranoprofen to the anionic SCL was confirmed by including pranoprofen in combination with various concentrations of taurine at a pH of 5.5 to 7.7. Further, all the test liquids having a pH of 5.5 to 7.7 were not confirmed to be cloudy, and showed a clear appearance property.

In the table, the unit of the added amount of each added component is "w/v%".

In the table, the unit of the added amount of each added component is "w/v%".

Test Example 3

The components shown in Table 4 were mixed in a usual manner to prepare a test solution. The appearance of each of the obtained test liquids was observed, and the turbidity (absorbance at 660 nm) was measured to evaluate the presence or absence of white turbidity.

The results obtained are shown in Table 4. As is clear from Table 4, in the case of pH 4.5 or less, white turbidity was confirmed in any of the test liquids containing pranoprofen. According to the results of the above Test Examples 1 and 2, it was found that pranoprofen and taurine and/or a salt thereof were contained, and the pH was set to 5.5 or more, whereby a clear appearance property was exhibited, and Pura was suppressed. Lofin is adsorbed to anionic SCL.

In the table, the unit of the added amount of each added component is "w/v%".

Claims (7)

An ophthalmic composition for anionic soft contact lenses, which comprises pranoprofen and/or a pharmaceutically acceptable salt thereof, and taurine and/or a pharmaceutically acceptable salt thereof, and has a pH of 7.7 or less. The ophthalmic composition for anionic soft contact lenses according to claim 1, which has a pH of 5.5 to 7.7. The ophthalmic composition for anionic soft contact lenses according to claim 1 or 2, wherein the taurine and/or its pharmaceutically acceptable salt contains 0.01 to 3 w/v%. The ophthalmic composition for anionic soft contact lenses according to any one of claims 1 to 3, which contains 0.001 to 0.5 w/v% of pranoprofen and/or a pharmaceutically acceptable salt thereof. The ophthalmic composition for an anionic soft contact lens according to any one of claims 1 to 4, which is an eye drop for an anionic soft contact lens. A method for inhibiting adsorption of pranoprofen and/or a pharmaceutically acceptable salt thereof to an anionic soft contact lens, characterized by comprising an anionic soft contact lens comprising pranoprofen and/or a pharmaceutically acceptable salt thereof To the ophthalmic composition, taurine and/or a pharmaceutically acceptable salt thereof is added, and the pH is adjusted to 7.7 or less. A liquid preparation for use in the manufacture of an ophthalmic composition for anionic soft contact lenses, which comprises pranoprofen and/or a pharmaceutically acceptable salt thereof, and taurine and/or a pharmaceutically acceptable salt thereof And the pH is 7.7 or less.